Press release

Press release – 22.09.2017

Theraclion comments on its 2017 half-year results

First Clinical Trial Combining Echotherapy and Imunotherapy to Treat Metastatic Breast Cancer

Publication of promising clinical trial results in a new thyroid indication

Expansion of Echotherapy Reimbursement Coverage in Germany

Echopulse® Covered by French National Health Insurance for Breast Fibroadenomas

Theraclion achieves strong sales and accelerates its commercial development

FDA Authorized Immunotherapy and Echotherapy Combination Study on Breast Cancer

More than 1,000 treatments and changes in the distribution of Theraclion's capital

First direct comparison of echotherapy with Echopulse® to surgery results

Presentation of U.S. clinical data supporting Echotherapy with Echopulse® for breast fibroadenomas